Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
PaperCitations, authors & open-access status
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 234 citations, 2017 year and closed oa status.
234
Citations
2017
Year
closed
OA Status